S-Evans Biosciences Co.,Ltd. Report issue

For profit Phase 2
Founded: China (2009)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2010
NCT01483248
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

S-Evans Biosicences Co.,Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Digestive System Diseases (Phase 2)

Fibrosis (Phase 2)

Gastrointestinal Diseases (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Diseases (Phase 2)

Lung Injury (Phase 2)

Multiple Organ Failure (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3